Frauke Bentzien

Title: Frauke Bentzien: Innovator in Cancer Treatment

Introduction

Frauke Bentzien is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and inventions. With a total of 2 patents, her work focuses on enhancing the efficacy of cancer therapies.

Latest Patents

One of her latest patents is titled "Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents." This invention is based on the discovery that the administration of a sphingosine-1-phosphate receptor antagonist (S1P) alongside at least one chemotherapeutic agent from the group of antimicrotubule agents provides an unexpectedly superior treatment for cancer. Antimicrobial agents such as taxane compounds, including paclitaxel and docetaxel, are known in the art, and her invention also provides methods for modulating the growth of selected cell populations, such as cancer cells. Another notable patent is related to "Antiangiogenic peptide agents," which provides novel antiangiogenic peptides corresponding to about 133 consecutive amino acids of the N-terminal sequence of growth hormone.

Career Highlights

Frauke has worked with esteemed institutions such as the University of California and Exelixis, Inc. Her research has significantly impacted the development of new cancer therapies, showcasing her dedication to improving patient outcomes.

Collaborations

Frauke has collaborated with notable individuals in her field, including Richard I. Weiner and Joseph A. Martial. Their combined expertise has contributed to the advancement of her innovative projects.

Conclusion

Frauke Bentzien's contributions to cancer treatment through her patents and collaborations highlight her role as a leading inventor in the medical field. Her work continues to pave the way for more effective cancer therapies.